Patents Issued in March 2, 2017
-
Publication number: 20170058027Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.Type: ApplicationFiled: May 16, 2016Publication date: March 2, 2017Applicant: AbbVie Inc.Inventors: Chengbin WU, Dominic J. AMBROSI, Chung-ming HSIEH, Tariq GHAYUR
-
Publication number: 20170058028Abstract: The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, that inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.Type: ApplicationFiled: November 20, 2014Publication date: March 2, 2017Inventors: Panayiotis Stevis, Jesper Gromada, Andrew J. Murphy, Yonaton Ray, Jee H. Kim, Ivan B. Lobov
-
Publication number: 20170058029Abstract: It is an object of the present invention to provide a chicken B cell that expresses a variety of human antibodies.Type: ApplicationFiled: May 1, 2015Publication date: March 2, 2017Inventors: Shuichi Hashimoto, Tomoaki Uchiki, Shigeshisa Kawata, Kenjiro Asagoshi, Takashi Yabuki, Hitomi Sano, Shunsuke Miyai, Naoki Takahashi, Aki Takesue, Atsushi Sawada
-
Publication number: 20170058030Abstract: In some aspects, mutant or variant Fc domains are provided that can exhibit increased affinity or selectivity for Fc?RIIB. The variant Fc domain may be a mutant IgG1 Fc domain. In some embodiments, a mutant or variant Fc domain may be present in a therapeutic antibody such as, e.g., an agonistic antibody. Additional methods for using and identifying mutant Fc domains are also provided.Type: ApplicationFiled: August 29, 2016Publication date: March 2, 2017Applicant: Research Development FoundationInventors: George GEORGIOU, Chang-Han LEE
-
Publication number: 20170058031Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.Type: ApplicationFiled: November 10, 2016Publication date: March 2, 2017Inventors: David John King, Alison WITTE, Heidi N. LEBLANC, Richard THEOLIS, Asna MASOOD, Mark YAMANAKA, Kyra D. ZENS, Sarah R. REED, Tim SPROUL, Chetana RAO-NAIK, David Passmore, Dawn M. TANAMACHI, Kristopher TOY
-
Publication number: 20170058032Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: November 11, 2016Publication date: March 2, 2017Applicant: Genentech, Inc.Inventors: Yvonne CHEN, Mark DENNIS, David DORNAN, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
-
Publication number: 20170058033Abstract: The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.Type: ApplicationFiled: August 18, 2016Publication date: March 2, 2017Inventors: Dale Lincoln Ludwig, Marshall Davenport Snavely, Yiwen Li, Juqun Shen, Vera Molkenthin
-
Publication number: 20170058034Abstract: Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E+ T cell by an HLA-E-restricted CD8+ T cell comprising contacting the HLA-E+ T cell and CD8+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of the HLA-E+ T cell, thereby inhibiting or enhancing, respectively, down-regulation of the antigen-activated HLA-E+ T cell. Compositions comprising agents which inhibit or enhance/activate, respectively, binding between (i) T cell receptor (TCR) on the surface of a CD8 T cell and (ii) a self peptide presented by HLA-E on the surface of a HLA-E+ T cell, and assays for identifying such agents, are provided.Type: ApplicationFiled: July 7, 2016Publication date: March 2, 2017Inventors: Hong Jiang, Leonard Chess
-
Publication number: 20170058035Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.Type: ApplicationFiled: February 27, 2015Publication date: March 2, 2017Applicant: MERUS N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robertus Cornelis ROOVERS
-
Publication number: 20170058036Abstract: Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof derived from 6G8G7 and 7C5B2 anti-DEspR variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo non-invasive imaging and/or assessments.Type: ApplicationFiled: August 24, 2016Publication date: March 2, 2017Applicant: Trustees of Boston UniversityInventors: Nelson Ruiz-Opazo, Victoria L.M. Herrera
-
Publication number: 20170058037Abstract: Methods of treating inflammatory conditions, disease and disorders are provided. Method include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat the inflammatory condition, disease or disorder.Type: ApplicationFiled: October 14, 2016Publication date: March 2, 2017Inventors: Michael Croft, Taylor Doherty, Shahram Salek-Ardakani
-
Publication number: 20170058038Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.Type: ApplicationFiled: August 31, 2016Publication date: March 2, 2017Inventors: Scott Ronald BRODEUR, Thomas B. FREEMAN, Gerald Henry NABOZNY, Meera RAMANUJAM, Paul SCHOLL, Juergen STEFFGEN
-
Publication number: 20170058039Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: November 2, 2016Publication date: March 2, 2017Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias LITZENBURGER, Sanjaya SINGH
-
Publication number: 20170058040Abstract: The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.Type: ApplicationFiled: September 6, 2016Publication date: March 2, 2017Inventors: LAI-XI WANG, WEI HUANG
-
Publication number: 20170058041Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.Type: ApplicationFiled: November 8, 2016Publication date: March 2, 2017Inventors: Mark Cunningham, Yiqing Feng, Katharine Heeringa, Jinquan Luo, Robert Rauchenberger, Mark Rutz, Lani San Mateo, Robert Sarisky, Raymond Sweet, Fang Teng, Alexey Teplyakov, Sheng-Jiun Wu
-
Publication number: 20170058042Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.Type: ApplicationFiled: February 8, 2016Publication date: March 2, 2017Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
-
Publication number: 20170058043Abstract: Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, bispecific antibodies are disclosed that are able to engage T-cells to destroy TAG-72-expressing malignant cells. Disclosed are bispecific antibodies that are able to engage T-cells to destroy TAG-72-expressing malignant cells. The antibodies can be engineered from fusion polypeptides comprising 1) variable domains of antibodies that specifically bind an immune cell antigen and 2) variable domains of antibodies that specifically bind TAG-72.Type: ApplicationFiled: November 19, 2015Publication date: March 2, 2017Inventor: Hatem SOLIMAN
-
Publication number: 20170058044Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.Type: ApplicationFiled: September 6, 2016Publication date: March 2, 2017Inventors: Ugur Sahin, Michael Koslowski, Özlem Türeci
-
Publication number: 20170058045Abstract: The present invention provides, inter alia, a method for cell-specific modulation of a target antigen. The method comprises contacting a target cell having the target antigen on the surface of the target cell with: (a) first multi-specific antigen-binding polypeptide comprising: (i) a cell-specific antigen binding domain (C1), (ii) a target antigen binding domain (T1); and (b) a second multi-specific antigen-binding polypeptide comprising: (i) a cell-specific antigen binding domain (C2), (ii) a target antigen binding domain (T2); wherein C1 and C2 interact with the same cell-specific antigen, and the cell-specific antigen and the target antigen are on the same target cell. Pharmaceutical compositions and kits thereof are also included in the present invention.Type: ApplicationFiled: February 20, 2015Publication date: March 2, 2017Inventors: Jesper GROMADA, Eric SMITH, Andrew MURPHY, Nicholas PAPADOPOULOS, Joel MARTIN, George YANCOPOULOS, Douglas MACDONALD, David BUCKLER
-
Publication number: 20170058046Abstract: Use of an inhibitor of the ErbB2 receptor for treatment or repair of nerves and/or nerve tissues is provided. The inhibitor includes an antibody, in particular, a monoclonal antibody, for example, Herceptin. A medicament for treatment or repair of nerves and/or nerve tissues can be formulated which includes an inhibitor of the ErbB2 receptor. A pharmaceutical kit may include a medicament having an inhibitor of the ErbB2 receptor and dosing instructions for administrating the medicament for treatment or repair of nerves and/or nerve tissues. Also provided are uses of an inhibitor of the ErbB2 receptor for increasing axon regeneration, preventing neuron or glial cell death, and/or stimulating Schwann cell proliferation in a nerve stump.Type: ApplicationFiled: May 4, 2015Publication date: March 2, 2017Inventors: James M. HENDRY, Eva PLACHETA, Tessa GORDON, Gregory H. BORSCHEL
-
Publication number: 20170058047Abstract: Methods of detecting and treating diseases and pathological conditions of the eye are disclosed. In particular a genetic variant of the HtrA1 gene is correlated to age related macular degeneration (AMD). In addition, biologically active agents capable of inhibiting HtrA1 activity are provided, and methods of treating diseases and pathological conditions of the eye are additionally disclosed.Type: ApplicationFiled: April 6, 2016Publication date: March 2, 2017Applicant: University of Utah Research FoundationInventors: Kang Zhang, Zhenglin Yang, Haoyu Chen, Dean Li
-
Publication number: 20170058048Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: July 11, 2016Publication date: March 2, 2017Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
-
Publication number: 20170058049Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.Type: ApplicationFiled: August 11, 2016Publication date: March 2, 2017Applicant: Genentech, Inc.Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
-
Publication number: 20170058050Abstract: Herein is reported a conjugate comprising a helicar motif amino acid sequence containing compound and an antibody that specifically binds to the helicar motif amino acid sequence characterized by a covalent bond between the helicar motif amino acid sequence containing compound and an amino acid residue in the CDR2 of the anti-helicar antibody, whereby the CDR2 is determined according to Kabat.Type: ApplicationFiled: July 1, 2016Publication date: March 2, 2017Applicant: Hoffmann-La Roche Inc.Inventors: ULRICH BRINKMANN, GUY GEORGES, EIKE HOFFMANN, GEORG TIEFENTHALER, EKKEHARD MOESSNER, STEFAN DENGL, ACHIM GAERTNER
-
Publication number: 20170058051Abstract: Herein is reported a conjugate of a haptenylated polypeptide toxin and an anti-hapten antibody, wherein a disulfide bond is formed between a cysteine residue either before or after the lysine residue that is used for hapten-conjugation and a cysteine residue in the CDR2 of the antibody, whereby the CDR2 is determined according to Kabat.Type: ApplicationFiled: July 1, 2016Publication date: March 2, 2017Applicant: Hoffmann-La Roche Inc.Inventors: ULRICH BRINKMANN, EIKE HOFFMANN, STEFAN DENGL, KLAUS MAYER
-
Publication number: 20170058052Abstract: The present invention provides cells, transgenic animals, including transgenic mammals and particularly rodents, comprising engineered immunoglobulin alleles. Mutations in the alleles are designed to compromise allelic exclusion and have potential to be exploited for the isolation of bispecific antibodies.Type: ApplicationFiled: August 24, 2016Publication date: March 2, 2017Inventors: Matthias Wabl, Bao Duong
-
Publication number: 20170058053Abstract: Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.Type: ApplicationFiled: September 28, 2016Publication date: March 2, 2017Inventors: Gregory Lazar, Gregory Moore
-
Publication number: 20170058054Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglubulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.Type: ApplicationFiled: November 14, 2016Publication date: March 2, 2017Applicant: RINAT NEUROSCIENCE CORP.Inventors: Weihsien HO, Jaume PONS, Arvind RAJPAL, Pavel STROP
-
MODIFIED CONJUGATED DIENE POLYMER, METHOD FOR PREPARING SAME, AND RUBBER COMPOSITION CONTAINING SAME
Publication number: 20170058055Abstract: Disclosed are a modified conjugated diene-based polymer represented by specific Chemical Formula and a method of preparing the same.Type: ApplicationFiled: October 22, 2015Publication date: March 2, 2017Applicant: LG Chem, Ltd.Inventors: Ro-Mi Lee, No-Ma Kim -
Publication number: 20170058056Abstract: The disclosure is directed to a set of multi-coordinating imidazole- and zwitterion-based ligands suited for surface-functionalizing quantum dots (QDs). The polymeric ligands are built using a one-step nucleophilic addition reaction between poly(isobutylene-alt-maleic anhydride) and distinct amine-containing functionalities.Type: ApplicationFiled: August 19, 2016Publication date: March 2, 2017Inventors: Hedi Mattoussi, Wentao Wang
-
Publication number: 20170058057Abstract: This invention relates to a functionalized resin composition having the formula P-X-S-W where S is a spacer selected from at least one of C2-C40 straight chain and branched alkyl, C6-C40 aromatics, butadiene, isoprene, and combinations thereof, P is a polymer backbone selected from at least one of dicyclopentadiene (DCPD)-based polymers, cyclopentadiene (CPD)-based polymers, DCPD-styrene copolymers, C5 homopolymers and copolymer resins, C5-styrene copolymer resins, terpene homopolymer or copolymer resins, pinene homopolymer or copolymer resins, C9 homopolymers and copolymer resins, C5/C9 copolymer resins, alpha-methylstyrene homopolymer or copolymer resins, and combinations thereof, X is one or more reactive groups, and W is a silane.Type: ApplicationFiled: March 6, 2015Publication date: March 2, 2017Inventors: Edward J. Blok, Ian C. Stewart, Anthony J. Dias, Yong Yang, Jingwen Zhang
-
Publication number: 20170058058Abstract: This invention relates to a process for the preparation of a silane-functionalized resin composition comprising the steps of mixing a polymer backbone, a silane, and a free radical initiator; and producing a silane-functionalized resin composition. The polymer backbone is selected from at least one of dicyclopentadiene (DCPD)-based polymers, cyclopentadiene (CPD)-based polymers, DCPD-styrene copolymers, C5 homopolymers and copolymer resins, C5-styrene copolymer resins, terpene homopolymer or copolymer resins, pinene homopolymer or copolymer resins, C9 homopolymers and copolymer resins, C5/C9 copolymer resins, alpha-methylstyrene homopolymer or copolymer resins, and combinations thereof.Type: ApplicationFiled: March 6, 2015Publication date: March 2, 2017Inventors: Edward J. Blok, Ian C. Stewart, David T. Harric
-
Publication number: 20170058059Abstract: The present invention provides a polymer compound for a conductive polymer comprising one or more repeating units “a” shown by the formula (1), and having a weight-average molecular weight in the range of 1,000 to 500,000. There can be provided a polymer compound for a conductive polymer having a specific superacidic sulfo group which is soluble in an organic solvent, and suitably used for a fuel cell or a dopant for a conductive material. wherein R1 represents a hydrogen atom or a methyl group; R2 represents any of a single bond, an ester group, and a linear, branched, or cyclic hydrocarbon group having 1 to 12 carbon atoms, the hydrocarbon group optionally containing an ether group, an ester group, or both; “Z” represents any of a single bond, a phenylene group, a naphthylene group, an ether group, and an ester group; and “a” is a number satisfying 0<a?1.0.Type: ApplicationFiled: August 8, 2016Publication date: March 2, 2017Applicant: SHIN-ETSU CHEMICAL CO., LTD.Inventors: Jun HATAKEYAMA, Masaki OHASHI, Takayuki NAGASAWA, Koji HASEGAWA
-
Publication number: 20170058060Abstract: A magnesium halide solution is disclosed. The magnesium halide solution comprises a magnesium halide, an oxygen-containing organic titanium compound, a hydroxyl-containing compound, and an organic solvent. The magnesium halide solution further comprises an organic heterocyclic compound. The organic solvent is a hydrocarbon and/or a halogenated hydrocarbon. The organic heterocyclic compound is at least one selected from a group consisting of a sulphur-containing organic heterocyclic compound, a nitrogen-containing organic heterocyclic compound, and an organic epoxy compound. The magnesium halide solution has a good stability, and can be used for preparing a catalyst for olefin polymerization and copolymerization reactions. The raw material of the magnesium halide solution is cheap and easy to be obtained. The preparing method is easy to be performed and is environment-friendly.Type: ApplicationFiled: April 29, 2015Publication date: March 2, 2017Applicants: China Petroleum & Chemical Corporation, Beijing Research Institute of Chemical Industry, China Petroleum & Chemical CorporationInventors: Shibo WANG, Junling ZHOU, Dongbing LIU, Lei ZHANG, Xinping LV, Bingquan MAO, Zhenjie LIU, Xin ZHOU, Changli ZHANG, Baoquan XING
-
Publication number: 20170058061Abstract: A composition includes a product of a condensation reaction between a thermal cross-linking agent and a product of hydrolysis and condensation polymerization of a compound represented by Chemical Formula 1: In Chemical Formula 1, the definitions of the substituents are the same as in the detailed description. Further, an electronic device and a thin film transistor include a cured material of the composition.Type: ApplicationFiled: August 17, 2016Publication date: March 2, 2017Applicant: Samsung Electronics Co., Ltd.Inventors: Eun Kyung LEE, Jiyoung JUNG, Jeong II PARK, Ajeong CHOI
-
Publication number: 20170058062Abstract: The present invention relates to polymers and to the use thereof in the form of active electrode material or in an electrode slurry as electrical charge storage means, the electrical charge storage means especially being secondary batteries. The secondary batteries are especially notable for high cell voltages, even when undergoing several charging and discharging cycles, and simple and scalable processing and production methods (for example by means of screen printing).Type: ApplicationFiled: August 25, 2016Publication date: March 2, 2017Applicant: Evonik Degussa GmbHInventors: Ulrich SCHUBERT, Andreas WILD, Bernhard HAEUPLER
-
Publication number: 20170058063Abstract: The invention relates to a pipe comprising at least one metallocene-catalyzed polyethylene resin, wherein the polyethylene resin has a multimodal molecular weight distribution and comprises at least two metallocene-catalyzed polyethylene fractions A and B, wherein fractions A and B are prepared in different reactors of at least two reactors connected in series, wherein the polyethylene resin comprises: at least 30% by weight and at most 50% by weight of the polyethylene fraction A, based on the total weight of the polyethylene resin, wherein fraction A has a melt index MI2 of at least 50 g/10 min as determined on the fluff of fraction A according to ISO 1133:1997 condition D at a temperature of 190° C. and under a load of 2.16 kg; wherein fraction B has a density of at most 0.9210 g/cm3; and wherein the polyethylene resin has a melt index MI5 of at least 0.10 g/10 min and of at most 1.0 g/10 min as determined according to ISO 1133:1997, condition T, at 190° C.Type: ApplicationFiled: April 23, 2015Publication date: March 2, 2017Inventors: Olivier Lhost, Jacques Michel
-
Publication number: 20170058064Abstract: The present invention relates to a process for polymerisation of olefins, in particular gas phase polymerisation of olefins, with the aid of a supported chromium oxide based catalyst.Type: ApplicationFiled: November 16, 2016Publication date: March 2, 2017Inventors: Stephan Detournay, Christophe Moineau
-
Publication number: 20170058065Abstract: To provide an effective process for producing a fluorinated polymer excellent in adhesion, by using a polymerization medium having a low ozone layer destruction potential. A process for producing a fluorinated polymer, which comprises polymerizing a monomer mixture comprising a fluorinated monomer and a polar functional group-containing monomer (excluding one having a fluorine atom) in a polymerization medium, wherein the polymerization medium contains a medium compound represented by CmH2m+1?xFx—O—CnH2n+1?yFy (wherein m is an integer of from 1 to 6, n is an integer of from 1 to 6, x is from 0 to (2m+1), y is from 0 to 2n, and (x+y) is at least 1), and wherein a solution obtained by dissolving the polar functional group-containing monomer in the polymerization medium is continuously or intermittently added to a polymerization reaction system.Type: ApplicationFiled: November 14, 2016Publication date: March 2, 2017Applicant: ASAHI GLASS COMPANY, LIMITEDInventors: Shigeru AIDA, Daisuke Taguchi
-
Publication number: 20170058066Abstract: A polymer compound for a conductive polymer including one or more repeating units “a” shown by the following general formula (1), and having a weight-average molecular weight in the range of 1,000 to 500,000, wherein R1 represents a hydrogen atom or a methyl group; R2 represents any of a single bond, an ester group, and a linear, branched, or cyclic hydrocarbon group having 1 to 12 carbon atoms and optionally containing either or both of an ether group and an ester group; R3 represents a linear or branched alkyl group having 1 to 4 carbon atoms with one or more hydrogen atoms in R3 being substituted by a fluorine atom(s); “Z” represents any of a single bond, a phenylene group, a naphthylene group, an ether group, and an ester group; and “a” is a number satisfying 0<a?1.0.Type: ApplicationFiled: August 4, 2016Publication date: March 2, 2017Applicant: SHIN-ETSU CHEMICAL CO., LTD.Inventors: Jun HATAKEYAMA, Takayuki FUJIWARA, Takayuki NAGASAWA, Koji HASEGAWA
-
Publication number: 20170058067Abstract: A wax dispersant for a toner including a polymer obtained by graft polymerization of a styrene-acrylic resin onto a hydrocarbon compound, wherein the styrene-acrylic resin has a structural segment derived from a saturated alicyclic compound, and a toner including a toner particle that contains a binder resin, a wax, and a polymer obtained by graft polymerization of a styrene-acrylic resin onto a hydrocarbon compound, wherein the styrene-acrylic resin has a structural segment derived from a saturated alicyclic compound.Type: ApplicationFiled: August 23, 2016Publication date: March 2, 2017Inventors: Takeshi Ohtsu, Kentaro Kamae, Ryuichiro Matsuo, Yosuke Iwasaki, Wakiko Katsumata, Masaharu Miura, Koh Ishigami, Yuichi Mizo, Kenta Mitsuiki
-
Publication number: 20170058068Abstract: Provided are functionalized polypropylene adhesive compositions having a desirable range of melt flow rate. These compositions are obtained by grafting at least one impact polypropylene copolymer or by co-grafting a blend containing at least one impact polypropylene copolymer and at least one random polypropylene copolymer. The polypropylene copolymer(s) are grafted with one or more ethylenically unsaturated carboxylic acids or derivatives of these acids, such as anhydrides. Maleic anhydride is a preferred grafting monomer. Also provided is a multilayer film or sheet structure containing at least one barrier layer and at least one adhesive layer produced from the functionalized polypropylene adhesive composition. The multilayer film or sheet structure may also contain at least one predominantly polypropylene-based layer.Type: ApplicationFiled: August 25, 2016Publication date: March 2, 2017Inventors: I-HWA LEE, Qian Deng
-
Publication number: 20170058069Abstract: An active energy ray-curable sealing agent composition, comprising (A) at least one unsaturated group-containing urethane oligomer having a number average molecular weight Mn of from 1,000 to 100,000 and a degree of unsaturation of from 0.Type: ApplicationFiled: April 16, 2015Publication date: March 2, 2017Inventors: Riichiro Maruta, Naoki Mori
-
Publication number: 20170058070Abstract: A method includes functionalizing edges of particles of an anisotropic material, exfoliating of the particles to form sheets of the material, aligning the sheets of material to form a network of multi-layered and aligned particles, and forming a structure out of the network of particles. A method includes functionalizing edges of particles of an anisotropic material, exfoliating the particles to form sheets of the material, aligning the sheets of material to form a network of multi-layered and aligned particles, and forming a structure out of the network of particles.Type: ApplicationFiled: August 31, 2015Publication date: March 2, 2017Inventors: Gabriel Iftime, John Steven Paschkewitz
-
Publication number: 20170058071Abstract: The present application provides the block copolymers and their application. The block copolymer has an excellent self assembling property and phase separation and various required functions can be freely applied thereto as necessary.Type: ApplicationFiled: December 8, 2014Publication date: March 2, 2017Applicant: LG Chem, Ltd.Inventors: Mi Sook Lee, Jung Keun Kim, Je Gwon Lee, No Jin Park, Se Jin Ku, Eun Young Choi, Sung Soo Yoon
-
Publication number: 20170058072Abstract: The invention provides a composition comprising: (a) a star polymer comprising: (i) a core portion comprising a polyvalent (meth) acrylic monomer, oligomer or polymer thereof or a polyvalent divinyl non-acrylic monomer, oligomer or polymer thereof; and (ii) at least two arms of polymerized alkyl (meth)acrylate ester; and (b) an oil of lubricating viscosity, wherein the core portion further comprises a functional group of formula (I): —CH2—C(R1)(C(?O)A)-Y—??(I) wherein R1 is hydrogen, a linear or branched alkyl group containing 1 to 5 carbon atoms; A is nitrogen or oxygen; and Y is a free radical leaving group selected from the group consisting of one or more atoms or groups of atoms which may be transferred by a radical mechanism under the polymerisation conditions, a halogen, an —O—N? group and an —S—C(?S)— group. The invention further provides the use of the composition in an oil of lubricating viscosity as a dispersant, a viscosity modifier or a precursor to a dispersant viscosity modifier.Type: ApplicationFiled: November 10, 2016Publication date: March 2, 2017Inventors: Daniel C. Visger, Mark Davies, David Price, Marina Baum, Barton J. Schober
-
Publication number: 20170058073Abstract: A method of synthesizing a resin including mixing a first solution including a melamine compound with a second solution including glutaraldehyde to form a third solution, heating the third solution to 35° C. to 90° C. in at a pH above 7 for 5 to 70 minutes, and cooling the third solution to room temperature.Type: ApplicationFiled: August 22, 2016Publication date: March 2, 2017Inventors: Rashid SALEEM, Ahmad ADNAN, Fahim Ashraf QURESHI
-
Publication number: 20170058074Abstract: A process of preparing a post-modified polycarbodiimide, the process includes combining a diisocyanate, a moisture scavenger, a monoisocyanate, and a catalyst in a reaction vessel; and heating the reaction vessel to a temperature and a time sufficient to form a capped polycarbodiimide wherein the capped polycarbodiimide has 0.25 wt % or less of free isocyanate groups; and the combining and heating are conducted in the absence of a solvent.Type: ApplicationFiled: February 19, 2015Publication date: March 2, 2017Inventors: Rajesh Kumar, Nikolay Lebedinski
-
Publication number: 20170058075Abstract: A composition for forming a polyiso-urea includes a capped polycarbodiimide and a polyol. The capped polycarbodiimide comprises the reaction product of a diisocyanate and a monoisocyanate in the presence of an oxygen scavenger and a carbodiimidization catalyst and in the absence of solvent, has 0.25 wt. % or less of free isocyanate groups, and is a liquid at 25° C. A polyiso-urea comprises the reaction product of the capped polycarbodiimide and the polyol.Type: ApplicationFiled: February 19, 2015Publication date: March 2, 2017Inventors: Rajesh Kumar, Nikolay Lebedinski
-
Publication number: 20170058076Abstract: A one-part moisture-curable polyurethane composition of the present technology comprises: a preliminary composition containing a urethane prepolymer (A); and an adhesion promoter (B); the adhesion promoter being a reaction product of a compound (b1) having three or more isocyanate groups; and a compound (b2) of at least one type of a compound selected from the group consisting of compounds represented by Formula (1) to (4) described below and hydrogenated compounds of compounds represented by Formula (1) to (3) described below; wherein a ratio (NCO/OH) between an isocyanate group (NCO) of the compound (b1) and a hydroxy group (OH) of the compound (b2) is 1.2 to 3.2; and a content of the adhesion promoter (B) being 0.1 to 10 parts by mass per 100 parts by mass of the preliminary composition.Type: ApplicationFiled: December 25, 2014Publication date: March 2, 2017Inventor: Kiminori Araki